Trigeminal neuralgia future or investigational therapies

Jump to: navigation, search

Trigeminal neuralgia Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Trigeminal Neuralgia from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Trigeminal neuralgia future or investigational therapies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Trigeminal neuralgia future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Trigeminal neuralgia future or investigational therapies

CDC on Trigeminal neuralgia future or investigational therapies

Trigeminal neuralgia future or investigational therapies in the news

Blogs on Trigeminal neuralgia future or investigational therapies

Directions to Hospitals Treating Trigeminal neuralgia

Risk calculators and risk factors for Trigeminal neuralgia future or investigational therapies

Despite being treated medically as well as surgery, many patients of trigeminal neuralgia suffer not only from refractory pain but also from the side effects of medications and post surgical complications. This has increased the demand for more precise treatments which, along with pain relief, can also improve the quality of life. Emerging treatment options currently under clinical investigation are a novel sodium channel blocker (CNV1014802) that selectively blocks the Nav1.7 sodium channel, as well as local botulinum neurotoxin type A injections. Non-pharmacological options may include non-invasive electrical stimulation with transcranial direct current stimulation (tDCS), or repetitive transcranial magnetic stimulation (rTMS). All these things are currently under investigation and require further evaluation.[1]

References

  1. Obermann, Mark; Katsarava, Zaza; Holle, Dagny (2017). "An update on emerging therapeutic options for the treatment of trigeminal neuralgia". Expert Opinion on Orphan Drugs. 5 (11): 859–863. doi:10.1080/21678707.2017.1394183. ISSN 2167-8707.



Linked-in.jpg